Home > Analyse
Actualite financiere : Actualite bourse

AstraZeneca: Oddo welcomes FDA's decision on Imfinzi

(CercleFinance.com) - Oddo BHF has confirmed its "buy" rating on the AstraZeneca share, raising its target price from 5580 pence to 5620 pence, the day after FDA approved Imfinzi for non-small stage III lung cancer.

The analyst pointed out that this is the only immunotherapy that is allowed for patients suffering from this disease, which would represent a market worth between four billion and five billion dollars.

According to the broker's analysts, the pharmaceutical company therefore has a unique competitive advantage in non-small cell lung cancer.

Copyright (c) 2018 CercleFinance.com. All rights reserved.